Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay

Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

(2016) Camille Guillerey et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy

(2015) S. Picaud et al.   CANCER RESEARCH

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

(2015) Jing Lu et al.   CHEMISTRY & BIOLOGY

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

(2015) Elodie Odore et al.   CLINICAL PHARMACOKINETICS

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

(2015) Camille Guillerey et al.   JOURNAL OF CLINICAL INVESTIGATION

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells

(2015) Alessandra Zingoni et al.   JOURNAL OF IMMUNOLOGY

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

(2015) E Morelli et al.   LEUKEMIA

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma

(2015) R H Prabhala et al.   LEUKEMIA

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors

(2015) R Gopalakrishnan et al.   ONCOGENE

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

(2015) Ariane Hammitzsch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300

(2015) Jonathan H. Shrimp et al.   ACS Medicinal Chemistry Letters

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

(2015) C C Bjorklund et al.   Blood Cancer Journal

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

(2015) Lei-lei Fu et al.   Oncotarget

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

(2015) Cinzia Fionda et al.   Oncotarget

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

(2015) Cinzia Fionda et al.   Biomed Research International

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

(2015) Anastasia Wyce et al.   Oncotarget

Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

(2014) Dennis L. Buckley et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction

(2014) S. Meng et al.   JOURNAL OF DENTAL RESEARCH

Strategies for modern biomarker and drug development in oncology

(2014) Alan D Smith et al.   Journal of Hematology & Oncology

Reactive Oxygen Species– and DNA Damage Response–Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1

(2014) Alessandra Soriani et al.   JOURNAL OF IMMUNOLOGY

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle

(2014) François Lamoureux et al.   Nature Communications

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

MicroRNAs in Cancer

(2013) Gianpiero Di Leva et al.   Annual Review of Pathology-Mechanisms of Disease

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Super-Enhancers in the Control of Cell Identity and Disease

(2013) Denes Hnisz et al.   CELL

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer

(2013) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Diverse functions of miR-125 family in different cell contexts

(2013) Yu-Meng Sun et al.   Journal of Hematology & Oncology

Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity

(2013) Yujie Liu et al.   NATURE MEDICINE

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Small-Molecule Inhibition of BRDT for Male Contraception

(2012) Martin M. Matzuk et al.   CELL

The role of natural killer cells in immunity against multiple myeloma

(2012) James Godfrey et al.   LEUKEMIA & LYMPHOMA

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors

(2012) H. S. Bandukwala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

(2011) A. Heinemann et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

MicroRNA-125b Potentiates Macrophage Activation

(2011) Aadel A. Chaudhuri et al.   JOURNAL OF IMMUNOLOGY

Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines

(2011) F. R. Santer et al.   MOLECULAR CANCER THERAPEUTICS

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor

(2010) Erin M. Bowers et al.   CHEMISTRY & BIOLOGY

Chemical Inducers of Targeted Protein Degradation

(2010) Kanak Raina et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

IRF4: Immunity. Malignancy! Therapy?

(2009) A. L. Shaffer et al.   CLINICAL CANCER RESEARCH

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D

(2008) Noam Stern-Ginossar et al.   NATURE IMMUNOLOGY

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

(2008) F. Pichiorri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA